Medirom Healthcare Technologies Inc

Medirom Healthcare Technologies Inc(MRM)股票分析

$0.284

-0.004 (-1.46%)收盤時

Loading chart…
最高
0.300
開盤
0.300
成交量加權均價
0.29
成交量
13.98K
市值
18.55M
最低
0.280
成交金額
4.03K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Medirom Healthcare Technologies Inc is a Japan-based holistic health services provider. The Company is a franchiser and operator of healthcare salons across Japan and is a preferred platform partner for large consumer brands, healthcare service providers and government entities. The Company mainly operates in two business segments. The Relaxation Salon Segment is engaged in the development of relaxation studios nationwide, centered on Re.Ra.Ku for the purpose of health management services. The Digital Preventative Healthcare Segment is involved in the sampling business, which includes brand promotion and consumer analysis for third party brands of corporate clients, government-sponsored specific health guidance program, utilizing internally-developed on-demand health monitoring smartphone application Lav, as well as MOTHER Tracker for fitness applications, and preventative healthcare services utilizing digital application and devices.

AI 分析 of Medirom Healthcare Technologies Inc (MRM)

賣出

Medirom Healthcare Technologies Inc (MRM) is not a good buy right now due to its extremely low RSI of 12.99, indicating it is oversold, and a staggering year-to-date change of -85.49%. The company's gross margin has improved to 99.65% in the last quarter, but the overall financial health is concerning with a debt-to-equity ratio of 174.83% and a current ratio of only 1.75, suggesting liquidity issues. The main risk is the significant decline in stock price, which has dropped 48.57% over the last 20 days, indicating a lack of investor confidence and potential further declines.

估值指標

Medirom Healthcare Technologies Inc(MRM)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
2.75
目前EV/EBITDA
0.00
高估
7.92
低估
-2.42

預期股價營收比

合理
5 年均值 P/S
0.04
目前P/S
0.00
高估
0.14
低估
-0.05

Alphio AI 對 MRM 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MRM

$1.40

情境價格

基

基準

基準 · 50%MRM

$1.32

情境價格

悲

悲觀

悲觀 · 25%MRM

$1.07

情境價格

事件時間軸

2026-02-27 (ET)

08:10:00

Medirom Healthcare Signs Agreement with Tools for Humanity, Projects $39 Million Income Over Two Years

2025-12-29 (ET)

08:30:00

MEDIROM Collaborates with World Foundation to Deploy Proof of Human Technology in Japan

2025-12-26 (ET)

18:00:00

Medirom Healthcare Partners with World Foundation to Deploy Proof of Human Technology

2025-10-29 (ET)

10:25:23

Medirom Healthcare to Introduce New Treasury Strategy Utilizing Cryptocurrency

2025-10-28 (ET)

08:36:02

Medirom Healthcare reports that more than 10,000 individuals have obtained World IDs at various locations.

資訊

MRM 常見問題 —— 由 Alphio AI 解答

Medirom Healthcare Technologies Inc is a Japan-based holistic health services provider. The Company is a franchiser and operator of healthcare salons across Japan and is a preferred platform partner for large consumer brands, healthcare service providers and government entities. The Company mainly operates in two business segments. The Relaxation Salon Segment is engaged in the development of relaxation studios nationwide, centered on Re.Ra.Ku for the purpose of health management services. The Digital Preventative Healthcare Segment is involved in the sampling business, which includes brand promotion and consumer analysis for third party brands of corporate clients, government-sponsored specific health guidance program, utilizing internally-developed on-demand health monitoring smartphone application Lav, as well as MOTHER Tracker for fitness applications, and preventative healthcare services utilizing digital application and devices. It operates in the Consumer Non-Cyclicals sector.

Medirom Healthcare Technologies Inc (MRM) is not a good buy right now due to its extremely low RSI of 12.99, indicating it is oversold, and a staggering year-to-date change of -85.49%. The company's gross margin has improved to 99.65% in the last quarter, but the overall financial health is concerning with a debt-to-equity ratio of 174.83% and a current ratio of only 1.75, suggesting liquidity issues. The main risk is the significant decline in stock price, which has dropped 48.57% over the last 20 days, indicating a lack of investor confidence and potential further declines.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易